ReviewActa pharmaceutica Sinica. B2026
Nanomaterial-driven spatiotemporal autophagy modulation: The dual-edged sword in precision cancer therapy.
Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autophagy-modulating nanomaterials have emerged as a promising therapeutic paradigm in oncology, offering precise intervention in tumor progression, metastasis, and treatment resistance. The therapeutic efficacy of these platforms is largely attributed to their context-dependent dual functionality. On one hand, they are capable of inducing cytotoxic autophagy, such as through the activation of oxidative stress or endoplasmic reticulum stress, leading to tumor cell death. On the other hand, they can inhibit cytoprotective autophagy, a crucial survival mechanism exploited by tumor cells, by impairing lysosomal function or perturbing cellular energy metabolism. A key advancement in this field is the ability of nanomaterials to achieve spatiotemporal control over autophagy modulation, allowing targeted regulation at specific tumor sites and disease stages. This review systematically summarizes the molecular mechanisms underlying these bidirectional effects, with particular emphasis on the modulation of selective autophagy pathways including mitophagy, and discusses how rational nanomaterial design adapted to tumor stage and microenvironment dictates therapeutic outcomes. Finally, we highlight major translational challenges, especially the lack of standardized characterization and the difficulty in precisely controlling autophagic responses, which must be addressed to facilitate the clinical translation of these innovative nanotherapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.